| CTLA-4 and PD-1 Antibodies Expressing Mesothelin-CAR-T Cells for Mesothelin Positive Advanced Solid Tumor (NCT03182803) | Shanghai Cell Therapy Research Institute | 2017-06-07 |
| CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor (NCT03179007) | Shanghai Cell Therapy Research Institute | 2017-06-07 |
| Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor (NCT04689100) | Shanghai JMT-Bio Inc. | 2017-04-11 |
| Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients (NCT03028103) | Epizyme, Inc. | 2017-03-27 |
| First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced/Metastatic Solid Tumors (NCT02977195) | Centre Leon Berard | 2017-01-09 |
| A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients (NCT04237805) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2016-11-14 |
| Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors (NCT02870036) | Haihe Biopharma Co., Ltd. | 2016-10-01 |
| A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors (NCT02836600) | Eli Lilly and Company | 2016-09-09 |
| An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study (NCT02884479) | SciClone Pharmaceuticals International (Cayman) Development Limited | 2016-08-01 |
| PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach) (NCT02862028) | Shanghai International Medical Center | 2016-08-01 |
| Phase I Study of TENPA in Advanced Solid Cancer (NCT02979392) | Yung-Jue Bang | 2016-05-02 |
| 64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets (NCT02735798) | Pamela Munster | 2016-04-01 |
| Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001) (NCT02553499) | Merck Sharp & Dohme LLC | 2015-11-12 |
| First in Human Study of M4344 in Participants With Advanced Solid Tumors (NCT02278250) | EMD Serono Research & Development Institute, Inc. | 2015-01-26 |
| Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies (NCT02189174) | Novartis Pharmaceuticals | 2014-08-07 |
| Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors (NCT02168725) | Traws Pharma, Inc. | 2014-06-01 |
| A Clinical Study of Paclitaxel Cationic Liposomes for the Treatment of Patients With Advanced Solid Tumors (NCT06632574) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2014-03-19 |
| Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas (NCT02076451) | Daiichi Sankyo | 2014-02-01 |
| A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas (NCT01877382) | Daiichi Sankyo | 2013-07-11 |
| Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients (NCT01769768) | Novartis Pharmaceuticals | 2013-04-01 |
| M6620 First in Human Study (NCT02157792) | EMD Serono Research & Development Institute, Inc. | 2012-12-10 |
| Study of Simmitecan Hydrochloride in the Treatment of Advanced Solid Tumor (NCT01832298) | Haihe Biopharma Co., Ltd. | 2012-12-01 |
| Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors (NCT01673438) | ImmunityBio, Inc. | 2012-07-01 |
| A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas (NCT01588678) | Daiichi Sankyo | 2012-04-01 |
| A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors (NCT01546428) | Novartis Pharmaceuticals | 2012-02-01 |
| A Study of BYL719 in Adult Patients With Advanced Solid Malignancies (NCT01387321) | Novartis Pharmaceuticals | 2011-09-22 |
| MSC2015103B in Solid Tumors (NCT01453387) | EMD Serono | 2011-09-01 |
| A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors (NCT02133625) | Dana-Farber Cancer Institute | 2011-08-01 |
| Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus (NCT01378377) | EMD Serono | 2011-05-27 |
| Safety and Pharmacokinetic Profiles of Two Formulations of CO-1.01 in Patients With Advanced Solid Tumors (NCT01392976) | Clovis Oncology, Inc. | 2011-04-01 |
| A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma. (NCT01237236) | Novartis Pharmaceuticals | 2010-12-21 |
| A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors (NCT01195376) | Novartis Pharmaceuticals | 2010-10-01 |
| Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid Tumors (NCT01455571) | Hanmi Pharmaceutical Company Limited | 2009-11-01 |
| A Study of BKM120 in Adult Japanese Patients With Advanced Solid Tumors (NCT01283503) | Novartis Pharmaceuticals | 2009-10-01 |
| A Phase I Study of Famitinib Malate in Patients With Solid Tumor (NCT01762280) | Jiangsu HengRui Medicine Co., Ltd. | 2009-06-01 |
| Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan (NCT00742105) | Novartis Pharmaceuticals | 2008-11-17 |
| Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid Tumors (NCT00739414) | Novartis Pharmaceuticals | 2008-07-01 |
| Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients (NCT01131364) | Philogen S.p.A. | 2008-06-01 |
| Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma (NCT00861783) | Traws Pharma, Inc. | 2008-06-01 |
| Phase 1 Study With Sorafenib and Sirolimus (NCT00509613) | Radboud University Medical Center | 2007-06-01 |
| Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies (NCT00449280) | University of Chicago | 2006-11-01 |
| A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan (NCT00503477) | AstraZeneca | 2005-10-01 |
| Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases (NCT00501605) | AstraZeneca | 2003-02-01 |
| A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors (NCT01755390) | Sanofi | 1999-10-01 |